Intrahepatic cholestasis of pregnancy (ICP) is a pregnancy-specific liver disorder associated with an increased risk of adverse fetal outcomes. It is characterised by raised maternal serum bile acids, which are believed to cause the adverse outcomes. ICP is commonly treated with ursodeoxycholic acid (UDCA). This study aimed to determine the fetal and maternal bile acid profiles in normal and ICP pregnancies, and to examine the effect of UDCA treatment. Matched maternal and umbilical cord serum samples were collected from untreated ICP (n = 18), UDCA-treated ICP (n = 46) and uncomplicated pregnancy (n = 15) cases at the time of delivery. Nineteen individual bile acids were measured using HPLC-MS/MS. Maternal and fetal serum bile acids are significantly raised in ICP compared with normal pregnancy (p = <0.0001 and <0.05, respectively), predominantly due to increased levels of conjugated cholic and chenodeoxycholic acid. There are no differences between the umbilical cord artery and cord vein levels of the major bile acid species. The feto-maternal gradient of bile acids is reversed in ICP. Treatment with UDCA significantly reduces serum bile acids in the maternal compartment (p = <0.0001), thereby reducing the feto-maternal transplacental gradient. UDCA-treatment does not cause a clinically important increase in lithocholic acid (LCA) concentrations. ICP is associated with significant quantitative and qualitative changes in the maternal and fetal bile acid pools. Treatment with UDCA reduces the level of bile acids in both compartments and reverses the qualitative changes. We have not found evidence to support the suggestion that UDCA treatment increases fetal LCA concentrations to deleterious levels.
References
[1]
Geenes V, Williamson C (2009) Intrahepatic cholestasis of pregnancy. World J Gastroenterol 15: 2049–2066.
[2]
Macias RI, Pascual MJ, Bravo A, Alcalde MP, Larena MG, et al. (2000) Effect of maternal cholestasis on bile acid transfer across the rat placenta-maternal liver tandem. Hepatology 31: 975–983.
[3]
Sewell RB, Hardy KJ, Smallwood RA, Hoffman NE (1980) Fetal bile salt metabolism: placental transfer of taurocholate in sheep. Am J Physiol 239: G354–357.
[4]
Sewell RB, Hardy KJ, Smallwood RA, Hoffman NE (1982) Fetal bile salt metabolism: placental transfer of dihydroxy bile salts in sheep. Am J Physiol 243: G172–175.
[5]
Cui T, Liu Y, Men X, Xu Z, Wu L, et al. (2009) Bile acid transport correlative protein mRNA expression profile in human placenta with intrahepatic cholestasis of pregnancy. Saudi Med J 30: 1406–1410.
[6]
Geenes VL, Dixon PH, Chambers J, Raguz S, Marin JJ, et al. (2011) Characterisation of the nuclear receptors FXR, PXR and CAR in normal and cholestatic placenta. Placenta 32: 535–537.
[7]
Patel P, Weerasekera N, Hitchins M, Boyd CA, Johnston DG, et al. (2003) Semi quantitative expression analysis of MDR3, FIC1, BSEP, OATP-A, OATP-C,OATP-D, OATP-E and NTCP gene transcripts in 1st and 3rd trimester human placenta. Placenta 24: 39–44.
[8]
Serrano MA, Macias RI, Briz O, Monte MJ, Blazquez AG, et al. (2007) Expression in human trophoblast and choriocarcinoma cell lines, BeWo, Jeg-3 and JAr of genes involved in the hepatobiliary-like excretory function of the placenta. Placenta 28: 107–117.
[9]
Xu Z, Ke JC, Xing AY (2008) [Study on relationship between expression of familial intrahepatic cholestasis 1 mRNA in placenta and Intrahepatic cholestasis of pregnancy]. Sichuan Da Xue Xue Bao Yi Xue Ban 39: 430–433.
[10]
Colombo C, Roda A, Roda E, Buscaglia M, dell'Agnola CA, et al. (1985) Correlation between fetal and maternal serum bile acid concentrations. Pediatr Res 19: 227–231.
[11]
Itoh S, Onishi S, Isobe K, Manabe M, Inukai K (1982) Foetomaternal relationships of serum bile acid pattern estimated by high-pressure liquid chromatography. Biochem J 204: 141–145.
[12]
Laatikainen TJ (1975) Fetal bile acid levels in pregnancies complicated by maternal intrahepatic cholestasis. Am J Obstet Gynecol 122: 852–856.
[13]
Shaw D, Frohlich J, Wittmann BA, Willms M (1982) A prospective study of 18 patients with cholestasis of pregnancy. Am J Obstet Gynecol 142: 621–625.
[14]
Brites D, Rodrigues CM, van-Zeller H, Brito A, Silva R (1998) Relevance of serum bile acid profile in the diagnosis of intrahepatic cholestasis of pregnancy in an high incidence area: Portugal. Eur J Obstet Gynecol Reprod Biol 80: 31–38.
[15]
Heikkinen J (1983) Serum bile acids in the early diagnosis of intrahepatic cholestasis of pregnancy. Obstet Gynecol 61: 581–587.
[16]
Heikkinen J, Maentausta O, Ylostalo P, Janne O (1981) Changes in serum bile acid concentrations during normal pregnancy, in patients with intrahepatic cholestasis of pregnancy and in pregnant women with itching. Br J Obstet Gynaecol 88: 240–245.
[17]
Laatikainen T, Ikonen E (1977) Serum bile acids in cholestasis of pregnancy. Obstet Gynecol 50: 313–318.
[18]
Lunzer M, Barnes P, Byth K, O'Halloran M (1986) Serum bile acid concentrations during pregnancy and their relationship to obstetric cholestasis. Gastroenterology 91: 825–829.
[19]
Reyes H, Sjovall J (2000) Bile acids and progesterone metabolites in intrahepatic cholestasis of pregnancy. Ann Med 32: 94–106.
[20]
Sjovall K, Sjovall J (1966) Serum bile acid levels in pregnancy with pruritus (bile acids and steroids 158). Clin Chim Acta 13: 207–211.
[21]
Bacq Y, Sentilhes L, Reyes H, Glantz A, Kondrackiene J, et al. (2012) Efficacy of Ursodeoxycholic Acid in Treating Intrahepatic Cholestasis of Pregnancy: A Meta-analysis. Gastroenterology 143: 1492–1501.
[22]
Chappell LC, Gurung V, Seed PT, Chambers J, Williamson C, et al. (2012) Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ 344: e3799.
[23]
Geenes VL, Lim YH, Bowman N, Tailor H, Dixon PH, et al. (2011) A placental phenotype for intrahepatic cholestasis of pregnancy. Placenta 32: 1026–1032.
[24]
Miragoli M, Kadir SH, Sheppard MN, Salvarani N, Virta M, et al. (2011) A protective antiarrhythmic role of ursodeoxycholic acid in an in vitro rat model of the cholestatic fetal heart. Hepatology 54: 1282–1292.
[25]
Sinakos E, Marschall HU, Kowdley KV, Befeler A, Keach J, et al. (2010) Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. Hepatology 52: 197–203.
[26]
Williamson C, Hems LM, Goulis DG, Walker I, Chambers J, et al. (2004) Clinical outcome in a series of cases of obstetric cholestasis identified via a patient support group. BJOG 111: 676–681.
[27]
Lucangioli SE, Castano G, Contin MD, Tripodi VP (2009) Lithocholic acid as a biomarker of intrahepatic cholestasis of pregnancy during ursodeoxycholic acid treatment. Ann Clin Biochem 46: 44–49.
[28]
Sinakos E, Lindor KD (2010) Bile acid profiles in intrahepatic cholestasis of pregnancy: is this the solution to the enigma of intrahepatic cholestasis of pregnancy? Am J Gastroenterol 105: 596–598.
[29]
Tribe RM, Dann AT, Kenyon AP, Seed P, Shennan AH, et al. (2010) Longitudinal profiles of 15 serum bile acids in patients with intrahepatic cholestasis of pregnancy. Am J Gastroenterol 105: 585–595.
[30]
Briz O, Serrano MA, MacIas RI, Gonzalez-Gallego J, Marin JJ (2003) Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem J 371: 897–905.
[31]
St-Pierre MV, Serrano MA, Macias RI, Dubs U, Hoechli M, et al. (2000) Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol 279: R1495–1503.
[32]
Serrano MA, Brites D, Larena MG, Monte MJ, Bravo MP, et al. (1998) Beneficial effect of ursodeoxycholic acid on alterations induced by cholestasis of pregnancy in bile acid transport across the human placenta. J Hepatol 28: 829–839.
